Apotex
Apotex Inc., a leading Canadian pharmaceutical company, is headquartered in Toronto, Ontario, Canada. Founded in 1974, Apotex has established itself as a key player in the global generic and specialty pharmaceuticals industry, with a strong presence in North America, Europe, and other international markets. The company is renowned for its extensive portfolio of over 300 generic medications, which are designed to provide affordable alternatives to brand-name drugs. Apotex's commitment to quality and innovation has led to significant milestones, including the development of complex generics and biosimilars. With a robust manufacturing infrastructure and a focus on research and development, Apotex has achieved a notable market position, consistently ranking among the top generic drug manufacturers in Canada and worldwide. Its dedication to improving patient access to essential medications underscores its reputation as a trusted leader in the pharmaceutical sector.
DitchCarbon Score
How does Apotex's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Apotex's score of 37 is higher than 58% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Apotex's reported carbon emissions
In 2023, Apotex reported total carbon emissions of approximately 40,219,000 kg CO2e for Scope 1 and about 15,572,000 kg CO2e for Scope 2. This reflects a slight decrease in emissions compared to 2022, where Scope 1 emissions were about 42,950,000 kg CO2e and Scope 2 emissions were approximately 16,173,000 kg CO2e. Over the past few years, Apotex has shown a commitment to reducing its carbon footprint, with ongoing evaluations of potential pathways to decarbonisation for both Scope 1 and Scope 2 emissions, aiming to establish near-term reduction targets by 2025. The emissions data is cascaded from Apotex Inc., the parent company, which provides a comprehensive overview of the organisation's climate impact. Apotex has not yet disclosed any Scope 3 emissions data, indicating a focus on direct and indirect emissions from their operations and energy use. As part of their climate commitments, Apotex is actively working towards net-zero emissions, with specific initiatives aimed at understanding and implementing effective decarbonisation strategies. The company is on track to set measurable targets for emissions reduction in the near term, demonstrating a proactive approach to addressing climate change.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Scope 1 | 44,817,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 20,870,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Apotex is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
